Wave Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) insider Chris Francis sold 208,836 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $13.67, for a total transaction of $2,854,788.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Wave Life Sciences Price Performance
WVE opened at $15.31 on Friday. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -29.44 and a beta of -1.10. The business has a 50-day moving average of $7.10 and a two-hundred day moving average of $6.22. Wave Life Sciences Ltd. has a 12 month low of $3.50 and a 12 month high of $15.92.
Wave Life Sciences (NASDAQ:WVE – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). Wave Life Sciences had a negative return on equity of 1,395.99% and a negative net margin of 66.50%. The firm had revenue of $19.69 million for the quarter, compared to analysts’ expectations of $24.80 million. During the same quarter in the previous year, the firm posted ($0.20) EPS. Equities research analysts anticipate that Wave Life Sciences Ltd. will post -1.02 earnings per share for the current year.
Institutional Trading of Wave Life Sciences
Wall Street Analysts Forecast Growth
WVE has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a research note on Thursday. Raymond James raised shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $13.00 to $22.00 in a research report on Wednesday. Mizuho reissued an “outperform” rating and set a $19.00 price target on shares of Wave Life Sciences in a research report on Tuesday, June 25th. B. Riley increased their price target on shares of Wave Life Sciences from $11.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. Finally, Leerink Partners increased their price target on shares of Wave Life Sciences from $20.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Wave Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.56.
Read Our Latest Research Report on Wave Life Sciences
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Read More
- Five stocks we like better than Wave Life Sciences
- Investing in Construction Stocks
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Comparing and Trading High PE Ratio Stocks
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What is a Bond Market Holiday? How to Invest and Trade
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.